SCHEMBL7235366

SCHEMBL7235366

COC(=O)C1Cc2cc3c(cc2C(c2ccc([N+](=O)[O-])cc2)=NN1)OCO3

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
MAPK1 P28482 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
ALOX15 P16050 1/20 0.49
NFKB1 P19838 1/20 0.49
CYP2C19 P33261 1/20 0.49
HIF1A Q16665 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
BLM P54132 1/20 0.49
PMP22 Q01453 1/20 0.49
TERT O14746 3/20 0.43
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5416313 0.83 MAPT (0.71) MAPTMAPK1MEN1KMT2ACYP1A2
SCHEMBL5416306 0.83 MAPT (0.71) MAPTMAPK1MEN1KMT2ACYP1A2
SCHEMBL7228129 0.81 MAPT (0.50) MAPTMAPK1MEN1KMT2ACYP1A2
SCHEMBL6994686 0.76 MAPT (0.47) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL7832525 0.74 MAPT (0.52) MAPTMAPK1MEN1KMT2ACYP1A2
SCHEMBL5429840 0.73 GRIA1 (0.60) MAPTMAPK1MEN1KMT2ACYP1A2
SCHEMBL6615773 0.73 GRIA1 (0.60) MAPTMAPK1MEN1KMT2ACYP1A2
SCHEMBL6991386 0.73 GRIA1 (0.60) MAPTMAPK1MEN1KMT2ACYP1A2
SCHEMBL8793610 0.73 GRIA1 (0.76) MAPTMAPK1MEN1KMT2ACYP1A2
SCHEMBL6987263 0.73 GRIA1 (0.76) MAPTMAPK1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6600036-B2 Treating diseases of the central nervous system. SCHERING AKTIENGESELLSCHAFT (DE) 2003-07-29 US disclosed
US-20020052364-A1 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2002-05-02 US disclosed
EP-0888356-B1 CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS SCHERING AG (DE) 2002-03-20 EP disclosed
US-6323197-B1 NON-COMPETITIVE INHIBITING OF THE AMPA RECEPTORS, THESE COMPOUNDS CAN BE USED AS MEDICAMENTS FOR TREATMENT OF THE CENTRAL NERVOUS SYSTEM SCHERING AKTIENGESELLSCHAFT (DE) 2001-11-27 US disclosed
EP-0888356-A1 CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 1999-01-07 EP disclosed
WO-1997028163-A1 CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052364-A1 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors GABRE, GABRA2, GABRB2 MAPT 999/4885MAPK1 2769/4885MEN1 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.